Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-12

AUTHORS

Roman Hájek, Richard Bryce, Sunhee Ro, Barbara Klencke, Heinz Ludwig

ABSTRACT

BACKGROUND: Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib monotherapy in heavily pretreated patients, the overall response rate was 23.7%, 37% of patients achieved ≥ minimal response and median overall survival (OS) was 15.6 months. Based on this study, carfilzomib was recently approved by the US Food and Drug Administration for the treatment of R/R MM. Herein we describe the trial design and rationale for a phase 3 randomized study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study), being conducted to compare OS after treatment with single-agent carfilzomib to best supportive care (BSC) regimen in R/R MM. METHODS: Patients must have received ≥3 prior regimens, must be responsive to at least 1 line of therapy, and be refractory to their most recent therapy. Eligible patients are randomized 1:1 to receive either carfilzomib (28-day cycles at 20 mg/m(2) IV on Days 1-2 of Cycle 1, escalating to 27 mg/m(2) IV on Days 8, 9, 15, and 16 and continuing at 27 mg/m(2) through Cycle 9 and Days 1, 2, 15, and 16 ≥ Cycle 10) or an active BSC regimen (corticosteroid treatment of prednisolone 30 mg, dexamethasone 6 mg, or equivalent every other day with optional cyclophosphamide 50 mg PO once daily). Patients will continue treatment until disease progression, unacceptable toxicity, or treatment discontinuation and will then enter long-term follow-up for survival. The primary endpoint is OS and secondary endpoints include progression-free survival, overall response rate, and safety. Disease assessments will be determined according to the International Myeloma Working Group Uniform Response Criteria with minimal response per European Blood and Marrow Transplantation Group criteria. CONCLUSIONS: This phase 3 trial will provide more rigorous data for carfilzomib, as this is the first carfilzomib study with OS as the primary endpoint and will not be confounded by crossover and will provide more robust secondary response and safety results that will add to the data set from prior phase 2 studies. FOCUS will facilitate regulatory approvals around the world and expand treatment options for patients with R/R MM. TRIAL REGISTRATION: EudraCT No. 2009-016840-38; NCT01302392. More... »

PAGES

415

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-12-415

DOI

http://dx.doi.org/10.1186/1471-2407-12-415

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036271222

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22992303


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital Brno", 
          "id": "https://www.grid.ac/institutes/grid.412554.3", 
          "name": [
            "Department of Internal Medicine -Haematooncology, University Hospital Brno and Faculty of Medicine Ostrava, Jihlavska 20, 625 00, Brno, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "H\u00e1jek", 
        "givenName": "Roman", 
        "id": "sg:person.07656611737.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07656611737.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Puma Biotechnology (United States)", 
          "id": "https://www.grid.ac/institutes/grid.476660.5", 
          "name": [
            "Onyx Pharmaceuticals, Inc, South San Francisco, CA, USA", 
            "Present affiliation: Puma Biotechnology, Inc, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bryce", 
        "givenName": "Richard", 
        "id": "sg:person.015635546561.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015635546561.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ro", 
        "givenName": "Sunhee", 
        "id": "sg:person.01152407436.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152407436.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc, South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klencke", 
        "givenName": "Barbara", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wilhelminen Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417109.a", 
          "name": [
            "Wilhelminen Hospital, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ludwig", 
        "givenName": "Heinz", 
        "id": "sg:person.01151356276.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151356276.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/leu.2008.291", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002132702", 
          "https://doi.org/10.1038/leu.2008.291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.111.039164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007009347"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010603266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-05-425934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011406947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-0386", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012429574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0300-2977(01)00140-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014629185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2009-10-163329", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018417468"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.1987.tb00784.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019665589"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0609.1987.tb00784.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019665589"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/clml.2010.n.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020280684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-1950", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027164449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2009-0203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029972695"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2007-01-065888", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030221068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2011.196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031416563", 
          "https://doi.org/10.1038/leu.2011.196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ce.s13838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034153611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi098", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034333613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq370", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035613102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq370", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035613102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra1011442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039702038"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-03-414359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040165478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2012.09232.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047125405"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-4086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047843351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-540-85772-3_2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049723656", 
          "https://doi.org/10.1007/978-3-540-85772-3_2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-540-85772-3_2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049723656", 
          "https://doi.org/10.1007/978-3-540-85772-3_2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.1998.00930.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051933965"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-12", 
    "datePublishedReg": "2012-12-01", 
    "description": "BACKGROUND: Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib monotherapy in heavily pretreated patients, the overall response rate was 23.7%, 37% of patients achieved\u2009\u2265\u2009minimal response and median overall survival (OS) was 15.6 months. Based on this study, carfilzomib was recently approved by the US Food and Drug Administration for the treatment of R/R MM. Herein we describe the trial design and rationale for a phase 3 randomized study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study), being conducted to compare OS after treatment with single-agent carfilzomib to best supportive care (BSC) regimen in R/R MM.\nMETHODS: Patients must have received \u22653 prior regimens, must be responsive to at least 1 line of therapy, and be refractory to their most recent therapy. Eligible patients are randomized 1:1 to receive either carfilzomib (28-day cycles at 20 mg/m(2) IV on Days 1-2 of Cycle 1, escalating to 27 mg/m(2) IV on Days 8, 9, 15, and 16 and continuing at 27 mg/m(2) through Cycle 9 and Days 1, 2, 15, and 16\u2009\u2265\u2009Cycle 10) or an active BSC regimen (corticosteroid treatment of prednisolone 30 mg, dexamethasone 6 mg, or equivalent every other day with optional cyclophosphamide 50 mg PO once daily). Patients will continue treatment until disease progression, unacceptable toxicity, or treatment discontinuation and will then enter long-term follow-up for survival. The primary endpoint is OS and secondary endpoints include progression-free survival, overall response rate, and safety. Disease assessments will be determined according to the International Myeloma Working Group Uniform Response Criteria with minimal response per European Blood and Marrow Transplantation Group criteria.\nCONCLUSIONS: This phase 3 trial will provide more rigorous data for carfilzomib, as this is the first carfilzomib study with OS as the primary endpoint and will not be confounded by crossover and will provide more robust secondary response and safety results that will add to the data set from prior phase 2 studies. FOCUS will facilitate regulatory approvals around the world and expand treatment options for patients with R/R MM.\nTRIAL REGISTRATION: EudraCT No. 2009-016840-38; NCT01302392.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2407-12-415", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "name": "Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)", 
    "pagination": "415", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "acc7fc3fee0c2bb856e1d0299458f36f16afb7643d64595eac0068679a5e242d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22992303"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-12-415"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036271222"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-12-415", 
      "https://app.dimensions.ai/details/publication/pub.1036271222"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2407-12-415"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-415'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-415'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-415'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-12-415'


 

This table displays all metadata directly associated to this object as RDF triples.

209 TRIPLES      21 PREDICATES      60 URIs      28 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-12-415 schema:about N54d7e8541f874a6bb91119bc6bd50eeb
2 N59d7260f9a684244beaeec871784c53b
3 Nb26f6bc8c9d1425c9d86e1f1bce758df
4 Nc1e7e71ef063493286eb12a727ef6a78
5 Nd5f43eb20baa4cd38bab2c6bc334dcaf
6 Nd8b4a5eb22804febad430c1fb3f47c50
7 Ndf5f1495cb764d5e85ee087e56b0063e
8 anzsrc-for:11
9 anzsrc-for:1102
10 schema:author N517480e9814c463883a45db716ccd98f
11 schema:citation sg:pub.10.1007/978-3-540-85772-3_2
12 sg:pub.10.1038/leu.2008.291
13 sg:pub.10.1038/leu.2011.196
14 sg:pub.10.1038/sj.leu.2404284
15 https://doi.org/10.1016/s0300-2977(01)00140-1
16 https://doi.org/10.1046/j.1365-2141.1998.00930.x
17 https://doi.org/10.1056/nejmra1011442
18 https://doi.org/10.1093/annonc/mdi098
19 https://doi.org/10.1093/annonc/mdq370
20 https://doi.org/10.1111/j.1365-2141.2012.09232.x
21 https://doi.org/10.1111/j.1600-0609.1987.tb00784.x
22 https://doi.org/10.1124/dmd.111.039164
23 https://doi.org/10.1158/0008-5472.can-06-4086
24 https://doi.org/10.1158/1078-0432.ccr-09-0822
25 https://doi.org/10.1158/1078-0432.ccr-10-1950
26 https://doi.org/10.1158/1078-0432.ccr-11-3007
27 https://doi.org/10.1182/blood-2007-01-065888
28 https://doi.org/10.1182/blood-2009-10-163329
29 https://doi.org/10.1182/blood-2012-03-414359
30 https://doi.org/10.1182/blood-2012-05-425934
31 https://doi.org/10.1634/theoncologist.2009-0203
32 https://doi.org/10.1634/theoncologist.2010-0386
33 https://doi.org/10.2147/ce.s13838
34 https://doi.org/10.3816/clml.2010.n.005
35 schema:datePublished 2012-12
36 schema:datePublishedReg 2012-12-01
37 schema:description BACKGROUND: Carfilzomib is a next-generation proteasome inhibitor with single-agent activity in patients with relapsed and refractory multiple myeloma (R/R MM). In PX-171-003-A1, a single-arm phase 2 study of carfilzomib monotherapy in heavily pretreated patients, the overall response rate was 23.7%, 37% of patients achieved ≥ minimal response and median overall survival (OS) was 15.6 months. Based on this study, carfilzomib was recently approved by the US Food and Drug Administration for the treatment of R/R MM. Herein we describe the trial design and rationale for a phase 3 randomized study, FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study), being conducted to compare OS after treatment with single-agent carfilzomib to best supportive care (BSC) regimen in R/R MM. METHODS: Patients must have received ≥3 prior regimens, must be responsive to at least 1 line of therapy, and be refractory to their most recent therapy. Eligible patients are randomized 1:1 to receive either carfilzomib (28-day cycles at 20 mg/m(2) IV on Days 1-2 of Cycle 1, escalating to 27 mg/m(2) IV on Days 8, 9, 15, and 16 and continuing at 27 mg/m(2) through Cycle 9 and Days 1, 2, 15, and 16 ≥ Cycle 10) or an active BSC regimen (corticosteroid treatment of prednisolone 30 mg, dexamethasone 6 mg, or equivalent every other day with optional cyclophosphamide 50 mg PO once daily). Patients will continue treatment until disease progression, unacceptable toxicity, or treatment discontinuation and will then enter long-term follow-up for survival. The primary endpoint is OS and secondary endpoints include progression-free survival, overall response rate, and safety. Disease assessments will be determined according to the International Myeloma Working Group Uniform Response Criteria with minimal response per European Blood and Marrow Transplantation Group criteria. CONCLUSIONS: This phase 3 trial will provide more rigorous data for carfilzomib, as this is the first carfilzomib study with OS as the primary endpoint and will not be confounded by crossover and will provide more robust secondary response and safety results that will add to the data set from prior phase 2 studies. FOCUS will facilitate regulatory approvals around the world and expand treatment options for patients with R/R MM. TRIAL REGISTRATION: EudraCT No. 2009-016840-38; NCT01302392.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree true
41 schema:isPartOf N9da27cdba70b4562b972b14f9d64d77f
42 Nbecf653c3462484a92ecf93fd7f40b1b
43 sg:journal.1024632
44 schema:name Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
45 schema:pagination 415
46 schema:productId N0834258b093b4bfcab1ca1d5cfc952f3
47 N36cbc6d68e664162940a511f7a3d48ee
48 N46fb7603587e42d29610dddafe73e481
49 N6d846444add2462ab7a4e7dfd9e7056e
50 Nf5b0eeb11e504a27b772ba70b1ab543d
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036271222
52 https://doi.org/10.1186/1471-2407-12-415
53 schema:sdDatePublished 2019-04-10T21:37
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher Nfaf26a6b13bd47a89d4aa961e9f13558
56 schema:url http://link.springer.com/10.1186%2F1471-2407-12-415
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N0153170b0c71449c9c76c72ef219aab6 rdf:first sg:person.01151356276.76
61 rdf:rest rdf:nil
62 N0834258b093b4bfcab1ca1d5cfc952f3 schema:name pubmed_id
63 schema:value 22992303
64 rdf:type schema:PropertyValue
65 N1d8df3d8c58a46c384772c721be520d9 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
66 schema:familyName Klencke
67 schema:givenName Barbara
68 rdf:type schema:Person
69 N24df8b433cd44e9bb231c94b03a72368 rdf:first sg:person.015635546561.24
70 rdf:rest N5f13655c20244c54b41800304347653c
71 N36cbc6d68e664162940a511f7a3d48ee schema:name doi
72 schema:value 10.1186/1471-2407-12-415
73 rdf:type schema:PropertyValue
74 N46fb7603587e42d29610dddafe73e481 schema:name readcube_id
75 schema:value acc7fc3fee0c2bb856e1d0299458f36f16afb7643d64595eac0068679a5e242d
76 rdf:type schema:PropertyValue
77 N517480e9814c463883a45db716ccd98f rdf:first sg:person.07656611737.80
78 rdf:rest N24df8b433cd44e9bb231c94b03a72368
79 N54d7e8541f874a6bb91119bc6bd50eeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Oligopeptides
81 rdf:type schema:DefinedTerm
82 N59d7260f9a684244beaeec871784c53b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Antineoplastic Agents
84 rdf:type schema:DefinedTerm
85 N5f13655c20244c54b41800304347653c rdf:first sg:person.01152407436.99
86 rdf:rest N602ea7d134034252b2faa0f439b59976
87 N602ea7d134034252b2faa0f439b59976 rdf:first N1d8df3d8c58a46c384772c721be520d9
88 rdf:rest N0153170b0c71449c9c76c72ef219aab6
89 N6d846444add2462ab7a4e7dfd9e7056e schema:name dimensions_id
90 schema:value pub.1036271222
91 rdf:type schema:PropertyValue
92 N9da27cdba70b4562b972b14f9d64d77f schema:issueNumber 1
93 rdf:type schema:PublicationIssue
94 Nb26f6bc8c9d1425c9d86e1f1bce758df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Humans
96 rdf:type schema:DefinedTerm
97 Nbecf653c3462484a92ecf93fd7f40b1b schema:volumeNumber 12
98 rdf:type schema:PublicationVolume
99 Nc1e7e71ef063493286eb12a727ef6a78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Clinical Protocols
101 rdf:type schema:DefinedTerm
102 Nd5f43eb20baa4cd38bab2c6bc334dcaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Multiple Myeloma
104 rdf:type schema:DefinedTerm
105 Nd8b4a5eb22804febad430c1fb3f47c50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Recurrence
107 rdf:type schema:DefinedTerm
108 Ndf5f1495cb764d5e85ee087e56b0063e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Research Design
110 rdf:type schema:DefinedTerm
111 Nf5b0eeb11e504a27b772ba70b1ab543d schema:name nlm_unique_id
112 schema:value 100967800
113 rdf:type schema:PropertyValue
114 Nfaf26a6b13bd47a89d4aa961e9f13558 schema:name Springer Nature - SN SciGraph project
115 rdf:type schema:Organization
116 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
117 schema:name Medical and Health Sciences
118 rdf:type schema:DefinedTerm
119 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
120 schema:name Cardiorespiratory Medicine and Haematology
121 rdf:type schema:DefinedTerm
122 sg:journal.1024632 schema:issn 1471-2407
123 schema:name BMC Cancer
124 rdf:type schema:Periodical
125 sg:person.01151356276.76 schema:affiliation https://www.grid.ac/institutes/grid.417109.a
126 schema:familyName Ludwig
127 schema:givenName Heinz
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151356276.76
129 rdf:type schema:Person
130 sg:person.01152407436.99 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
131 schema:familyName Ro
132 schema:givenName Sunhee
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152407436.99
134 rdf:type schema:Person
135 sg:person.015635546561.24 schema:affiliation https://www.grid.ac/institutes/grid.476660.5
136 schema:familyName Bryce
137 schema:givenName Richard
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015635546561.24
139 rdf:type schema:Person
140 sg:person.07656611737.80 schema:affiliation https://www.grid.ac/institutes/grid.412554.3
141 schema:familyName Hájek
142 schema:givenName Roman
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07656611737.80
144 rdf:type schema:Person
145 sg:pub.10.1007/978-3-540-85772-3_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049723656
146 https://doi.org/10.1007/978-3-540-85772-3_2
147 rdf:type schema:CreativeWork
148 sg:pub.10.1038/leu.2008.291 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002132702
149 https://doi.org/10.1038/leu.2008.291
150 rdf:type schema:CreativeWork
151 sg:pub.10.1038/leu.2011.196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031416563
152 https://doi.org/10.1038/leu.2011.196
153 rdf:type schema:CreativeWork
154 sg:pub.10.1038/sj.leu.2404284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033553106
155 https://doi.org/10.1038/sj.leu.2404284
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1016/s0300-2977(01)00140-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014629185
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1046/j.1365-2141.1998.00930.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051933965
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1056/nejmra1011442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039702038
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1093/annonc/mdi098 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034333613
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1093/annonc/mdq370 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035613102
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1111/j.1365-2141.2012.09232.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047125405
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1111/j.1600-0609.1987.tb00784.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019665589
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1124/dmd.111.039164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007009347
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1158/0008-5472.can-06-4086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047843351
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1158/1078-0432.ccr-09-0822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010603266
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1158/1078-0432.ccr-10-1950 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027164449
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1158/1078-0432.ccr-11-3007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026589995
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1182/blood-2007-01-065888 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030221068
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1182/blood-2009-10-163329 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018417468
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1182/blood-2012-03-414359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040165478
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1182/blood-2012-05-425934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011406947
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1634/theoncologist.2009-0203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029972695
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1634/theoncologist.2010-0386 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012429574
192 rdf:type schema:CreativeWork
193 https://doi.org/10.2147/ce.s13838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034153611
194 rdf:type schema:CreativeWork
195 https://doi.org/10.3816/clml.2010.n.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020280684
196 rdf:type schema:CreativeWork
197 https://www.grid.ac/institutes/grid.412554.3 schema:alternateName University Hospital Brno
198 schema:name Department of Internal Medicine -Haematooncology, University Hospital Brno and Faculty of Medicine Ostrava, Jihlavska 20, 625 00, Brno, Czech Republic
199 rdf:type schema:Organization
200 https://www.grid.ac/institutes/grid.417109.a schema:alternateName Wilhelminen Hospital
201 schema:name Wilhelminen Hospital, Vienna, Austria
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
204 schema:name Onyx Pharmaceuticals, Inc, South San Francisco, CA, USA
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.476660.5 schema:alternateName Puma Biotechnology (United States)
207 schema:name Onyx Pharmaceuticals, Inc, South San Francisco, CA, USA
208 Present affiliation: Puma Biotechnology, Inc, Los Angeles, CA, USA
209 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...